Goldman Sachs Starts Amylin Pharmaceuticals (AMLN) at Sell, Sees 36% Downside

Article Stock Quotes (1) Comments (0)

Goldman Sachs initiates coverage on Amylin Pharmaceuticals (NASDAQ: AMLN) with a Sell rating and $10 price target, suggesting 36% downside.

The firm foresee more regulatory and commercial risk than the Street to Bydureon.

For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.

Shares of Amylin Pharmaceuticals closed at $16.07 yesterday, with a 52 week range of $9.51-$24.21.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Maxim Group Starts Canadian Solar (CSIQ) at Buy
• Workday (WDAY) Success Continues but Valuation Lofty, Goldman Maintains Neutral
• Goldman Sachs Downgrades Aixtron (AIXG) to Neutral

Create E-mail Alert Related Categories

Hot New Coverage, New Coverage

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?